Systems and methods for optimizing insulin dosage

US10368745B2 · kind B2 · utility

Assignee

• Roche Diabetes Care, Inc. · US

Inventors

• Steven Bousamra · Carmel, US
• Stefan Weinert · Pendleton, US
• Juergen Rasch-Menges · Schwetzingen, DE
• P. Douglas Walling · Indianapolis, US
• John F. Price · Wilmington, US
• Heino Eikmeier · Lorsch, DE
• Birgit Kraeling
• Karl Werner · Stuvsta-Snättringe, SE
• Ulrich Porsch · Weinheim, DE

Key dates

• Filing date: Feb 2, 2018
• Grant date: Aug 6, 2019
• Expiry date: Feb 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/006
• WIPO field: Medical technology
• WIPO sector: Instruments

Abstract

Embodiments of a testing method for diabetics to optimize their administered insulin dosage comprise collecting sampling sets of biomarker data, each sampling set comprising a sufficient plurality of non-adverse sampling instances and each sampling instance comprising an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when biomarker sampling parameters fall within the target biomarker range.